RECURSION PHARMACEUTICALS, INC. (RXRX) › Cash & EquivalentsRECURSION PHARMACEUTICALS, INC. (RXRX) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2020: $262.13M2021: $285.12M2022: $549.91M2023: $391.56M2024: $594.35M2025: $743.29M$743.29M2020Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$743.29M+25.1%2024$594.35M+51.8%2023$391.56M-28.8%2022$549.91M+92.9%2021$285.12M+8.8%2020$262.13M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share